Gemcitabine plus nab‑paclitaxel with or without pitavastatin for unresectable pancreatic adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open‑label Phase 1 trial adds pitavastatin to patients who are already receiving a gemcitabine‑based regimen (commonly gemcitabine with nab‑paclitaxel) to determine the recommended Phase 2 dose. Eligible participants have unresectable, recurrent, or metastatic pancreatic adenocarcinoma and must have completed 2–4 cycles of gemcitabine‑based therapy without radiographic progression. The study uses dose escalation and close safety monitoring with laboratory tests and imaging to identify tolerable dosing and track adverse events and tumor response per RECIST 1.1. The primary focus is on safety and dose selection, with secondary endpoints including preliminary anti‑tumor activity and feasibility of the combination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old
* Provision of a signed and dated ICF by the participant
* Has a diagnosis of histologically or cytologically confirmed metastatic, recurrent, or locally advanced PDAC
* Receiving a gemcitabine-based treatment regimen for a minimum of 2 and a maximum of 4 cycles without radiographic progression (ie SD or better).
* Measurable disease per RECIST 1.1
* Adequate organ (hematologic, hepatic, renal) function defined below:
* Hemoglobin ≥ 9.0 g/dL (transfusion is allowed)
* Platelets ≥ 100,000/mcL (transfusion is allowed)
* ANC ≥ 1500/mcL
* AST/ALT ≤ 3 x ULN (≤ 5 x ULN is allowable in cases of liver metastasis or Gilbert's Syndrome)
* Serum bilirubin ≤ 1.5 x ULN
* Serum albumin ≥ 3.0 g/dL
* Serum creatinine ≤ 1.5 x ULN OR creatinine clearance \> 60 mL/min
* ECOG PS 0-2
* 2 lines or less of prior treatment. Prior curative intent treatment (surgery and, if given in the adjuvant setting, systemic therapy and/or radiation) is permitted, regardless of time to recurrence, and does not constitute a line of therapy. This includes participants with residual disease after surgery, who received systemic therapy, chemoembolization, or radiotherapy.

Exclusion Criteria:

* Uncontrolled significant clinical illness
* Clinically significant autoimmune disease
* Major surgery within 4 weeks of the first dose of registration
* Known prior malignancy active within the previous 3 years, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
* Concomitant use of statin therapy (to be discontinued 2 weeks prior to the start of C1D1).
* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HbsAg) are eligible.
* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
* Patients with a known history of HIV.
* Known active metastases in the central nervous system (unless stable by brain imaging studies for at least 1 month after last treatment)
* Patients with QT interval corrected by Fridericia's formula (QTcF) \> 470 msec for both men and women on screening ECG are excluded.
* A woman of childbearing potential who has a positive pregnancy test prior to initiating study treatment.
* Breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening visit through 5 months after the last dose of study treatment.
* Medicines known to inhibit or induce either CYP2C8, CYP2C9, or CYP3A4
* History of prior organ or stem cell transplant.
* Has an active infection requiring systemic therapy. Systemic treatment used prophylactically is allowable.
* Patients who are unable to swallow or retain oral medication.

Where it's running

• Chao Family Comprehensive Cancer Center, University of California, Irvine
  Orange, California, United States Recruiting

Study contacts

• Principal investigator: Jennifer Valerin, MD, PhD — Chao Family Comprehensive Cancer Center
• Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
• Email: ucstudy@uci.edu
• Phone: 1-877-827-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.